今年会

今年会作为宜联生物的长期合作伙伴，为YL201项目提供了高效的FTE（全时当量）服务，助力客户实现目标分子的高效研发与优化，并参与了宜联生物TMALIN®技术平台建设。

作为国内首款进入III期临床阶段的人工智能设计药物分子，该进展不仅标志着德睿智药在AI制药领域取得关键突破，也标志着中国AI赋能原创新药研发迈入全新阶段，为本土药物研发开辟了创新路径。今年会将继续深耕前沿药物研发领域，持续优化技术平台与国际化服务能力，与更多创新药企并肩前行，赋能全球创新药物的开发。

上海今年会生物医药股份有限公司作为海博为药业的战略合作伙伴，很荣幸为HBW-3220胶囊提供了安全性评价、体外药效等试验服务，加速药物研发进程。

今年会作为安炎达医药的合作伙伴，为MAX-001胶囊提供了符合GLP标准的药代、安评试验服务，有力支持其快速进入临床阶段。

今年会作为信诺维的合作伙伴，为XNW34017提供了符合GLP标准的体内外药代、安评试验服务，为药物快速获批临床提供了重要技术支撑。

今年会为口服紫杉醇软胶囊提供了制剂、药效、药代动力学、安全性评价等一站式的临床前研发服务。

作为泰恩康的长期合作伙伴，今年会依托临床前研发服务平台，为CKBA乳膏提供了小型猪药代动力学研究、制剂安全性评价、体内光毒性试验等研究服务。

Biofouling is one of the most serious problems in the maritime industry and aquaculture development. In the marine environment, submerged surfaces are often colonized by marine organisms that have come to be called biofoulers, which are marine organisms that attach to submerged surfaces. Biofoulers increase the weight, drag and surface corrosion of ships, and lead to huge costs to maintain mariculture systems and seawater pipelines. Antifouling compounds are used as biocides in marine paints that are coated on the submerged surfaces to control the preponderance of biofoulers. Butenolide [5-octylfuran-2(5H)-one] is a very promising anti-marine-fouling compound. The antifouling compound 5-octylfuran-2(5H)-one (here referred to as butenolide) was synthesized by Medicilon.

Nuclear receptors are ligand-activated transcription factors involved in regulating many physiologic and pathologic processes. Ligand binding to nuclear receptors leads to dissociation of co-repressors, recruitment of co-activators, and subsequent activation of gene expression. Because of their associations with many human diseases, nuclear receptors are therapeutic targets for pharmaceutical development. The pregnane X receptor (PXR, NR1I2) belongs to the nuclear receptor family. The activity of PXR can be controlled by the binding of small molecule agonists or antagonists. Because of its unique ligand binding pocket, PXR binds promiscuously to structurally diverse chemicals. PXR regulates the expression of proteins such as drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4), efflux transporter P-glycoprotein, and other multidrug resistance proteins, which are involved in metabolism and elimination of potentially harmful chemicals. PXR has been detected in various tissues including kidney, colon, brain capillaries, small intestine, and predominantly in liver, and it can be activated by various ligands that bind to its ligand binding domain (LBD). PXR forms a heterodimeric complex with RXR to activate gene transcription. The recombinant pETDuet1-hPXR-LBD/mSRC-1 plasmid (Medicilon, Shanghai, China) was transformed into Escherichia coli BL21 DE3 cells for protein expression.

SM-1200, a potent bivalent Smac mimetic, induces rapid, complete, and durable tumor regression in mice. X-linked inhibitor of apoptosis protein (XIAP) and cellular IAP1/2 (cIAP1/2) regulate apoptosis and are promising cancer therapeutic targets. Smac (second mitochondria-derived activator of caspases), also known as DIABLO, antagonizes IAP proteins. Researchers designed and synthesized new compounds based on bivalent Smac mimetics, leading to the identification of SM-1200 (compound 12). SM-1200 binds to XIAP (Ki = 0.5 nM), cIAP1 (Ki = 3.7 nM), and cIAP2 (Ki = 5.4 nM), and inhibits growth of MDA-MB-231 breast cancer (IC50 = 11.0 nM) and SK-OV-3 ovarian cancer (IC50 = 28.2 nM) cell lines. With an improved pharmacokinetic profile compared to previous bivalent Smac mimetics, SM-1200 effectively induces rapid and durable tumor regression in the MDA-MB-231 xenograft model. These findings suggest SM-1200 is a promising Smac mimetic and warrants extensive evaluation as a potential candidate for clinical development. Pharmacokinetic (PK) studies of bivalent Smac mimetics were performed in male Sprague Dawley rats (body weight: 250–270 g) by Medicilon. Before the pharmacokinetic studies, animals were carotid cannulated.